Randomized trial · people
Cagrilintide with semaglutide: 17.1% weight loss at 2.4 mg, week 20
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this early 20-week trial, adding cagrilintide to semaglutide 2.4 mg brought more weight loss than semaglutide with placebo, and the share of people with side effects was similar between groups.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 96
- Published
- 2021
- Journal
- Lancet
What they tested
The team tested whether adding weekly cagrilintide shots to semaglutide 2.4 mg was safe and tolerable, and how the two drugs behaved in the body together.
How the study was done
A randomized, double-blind, placebo-controlled phase 1b trial at one US center in 96 otherwise healthy adults aged 18-55 with a BMI of 27.0-39.9 kg/m2. In six cohorts, people got weekly cagrilintide (0.16 to 4.5 mg) or placebo (a dummy shot), always with weekly semaglutide 2.4 mg, with doses raised over 16 weeks, then 4 weeks at the target dose and 5 weeks of follow-up, with no diet or exercise program.

Model. Individual results vary.
What they found
Side effects were common in both groups: 69 of 71 people (97%) on cagrilintide and 23 of 24 (96%) on placebo had at least one, mostly mild to moderate, and 207 (37%) of the 566 events were gut-related. At week 20, weight fell 15.7% in the 1.2 mg arm and 17.1% in the 2.4 mg arm vs 9.8% in pooled placebo, an estimated difference of -6.0% and -7.4%; the 4.5 mg arm lost 15.4% vs 8.0% on its matched placebo (difference -7.4%). Cagrilintide levels rose in line with dose, its half-life (time for blood levels to halve) was 159-195 h, and it did not change semaglutide levels or clearance. Blood sugar measures improved in all groups regardless of cagrilintide dose.
What it doesn’t show
This was a small, short early-phase trial in otherwise healthy adults at a single center, and weight change was an exploratory endpoint, not the main one. It was funded by Novo Nordisk.
The paper
Enebo et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021.
The compounds
More studies on Cagrilintide
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- Every study on Cagrilintide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.